Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Allopregnanolone Regenerative Therapeutic for Early Alzheimer's Disease: Intramuscular Study (Allo-IM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03748303
Recruitment Status : Recruiting
First Posted : November 20, 2018
Last Update Posted : January 29, 2020
Sponsor:
Collaborators:
University of Southern California
Alzheimer's Association
Information provided by (Responsible Party):
Roberta Brinton, University of Arizona

Brief Summary:
The purpose of this study is to identifying the intramuscular dose equivalent to the 4mg intravenous dose and assess its safety and tolerability as a weekly injection.

Condition or disease Intervention/treatment Phase
Alzheimer Dementia Drug: Allopregnanolone Phase 1

Detailed Description:

The purpose of this bridging study is to advance the therapeutic development of Allopregnanolone (Allo) by using the intramuscular (IM) route of administration as an alternative to the intravenous (IV) route. In order to identify the equivalent IM dose we will conduct pharmacokinetic (PK) analysis previously informed by simulations and modeling. We will recruit a total of 12 participants, both males and females equally distributed, into this single-arm, open-label study.

PK analysis and dose finding will take place for the initial 4 weeks; some participants may not require all 4 weeks of initial dosing to establish maintenance dose. Once maintenance dose is established all participants will receive weekly administration of Allo IM until they complete 12 weeks total of Allo exposure (5 or 6 clinic visits and 6 or 7 home-nurse visits).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Intervention Model: Single Group Assignment
Intervention Model Description: Single-arm, open-label study
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Allopregnanolone Regenerative Therapeutic for Early Alzheimer's Disease: IV to IM Bridging Study
Actual Study Start Date : October 1, 2019
Estimated Primary Completion Date : August 2020
Estimated Study Completion Date : October 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Allo IM cohort
Allopregnanolone 4-18mg IM, weekly, for 12 weeks.
Drug: Allopregnanolone
Administration of weekly IM injections of Allopregnanolone.
Other Name: Allo




Primary Outcome Measures :
  1. Safety - Adverse events [ Time Frame: From baseline to visit 16 (14 weeks) ]
    Incidence and severity of treatment emergent adverse events assessed weekly.

  2. Safety - clinical laboratory measures [ Time Frame: From Baseline to visit 16 (14 weeks) ]
    Proportion of subjects exceeding pre-established critical laboratory values.

  3. Safety - clinical assessment [ Time Frame: From Baseline to visit 16 (14 weeks) ]
    Proportion of subjects with abnormal findings in physical/neurological exams, vital signs and electrocardiograms.


Secondary Outcome Measures :
  1. Pharmacokinetic parameter - Cmax [ Time Frame: Visits 3 - 6 (up to 4 weeks) ]
    Determine maximum serum concentration of Allo after IM administration of each dose.

  2. Pharmacokinetic parameter - AUC [ Time Frame: Visits 3 - 6 (up to 4 weeks) ]
    Determine the area under the curve after each IM administration of Allo.

  3. Pharmacokinetic parameter - Tmax [ Time Frame: Visits 3 - 6 (up to 4 weeks) ]
    Determine the time at which Cmax is attained.

  4. Pharmacokinetic parameter - Clearance [ Time Frame: Visits 3 - 6 (up to 4 weeks) ]
    Pharmacokinetic measurement of the volume of plasma from which Allo is completely removed per unit time.

  5. Pharmacokinetic parameter - Volume of distribution [ Time Frame: Visits 3 - 6 (up to 4 weeks) ]
    Determine the volume of distribution at steady state of Allo.

  6. Satisfaction and feasibility of home nurse survey [ Time Frame: Visits 8-9 and 11-15 (up to 8 weeks) ]
    Standardized patient satisfaction questionnaire to assess the feasibility of home-health care visits to administer the study medication and its desirability by participants and caregivers. Levels of satisfaction measured on a 5-point scale (1 = lowest satisfaction, 5 = greatest).


Other Outcome Measures:
  1. MRI brain volumes [ Time Frame: Baseline to visit 16 (14 weeks) ]
    To evaluate MRI-based brain volumes 1-week before before and 1-week after the administration of Allo IM for 12 weeks (total assessment period of 14 weeks).

  2. Cambridge Neuropsychological Test Automated Battery (CANTAB) Paired Associates Learning (PAL) [ Time Frame: Baseline to visit 16 (14 weeks) ]
    Test to evaluate changes in cognition

  3. Mini-Mental State Exam (MMSE) [ Time Frame: Baseline to visit 16 (14 weeks) ]
    Test to evaluate changes in cognition.

  4. Alzheimer's Disease Assessment Scale Cognitive Subscale 14 (ADAS-Cog14) [ Time Frame: Baseline to visit 16 (14 weeks) ]
    Well known test to evaluate changes in cognition. Scores on this 14 item test range from 0 (best) to 85 (worse); a positive change indicates cognitive worsening.

  5. Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) [ Time Frame: Baseline to visit 16 (14 weeks) ]
    Clinical scale that rates the severity of dementia as absent, questionable, mild, moderate, or severe (CDR score of 0, 0.5, 1, 2, or 3, respectively).

  6. Cogstate Alzheimer's battery [ Time Frame: Baseline to visit 16 (14 weeks) ]
    Test to evaluate changes in cognition.

  7. Activities of daily living [ Time Frame: Baseline to visit 16 (14 weeks) ]
    To assess activities of daily living per the Alzheimer's Disease Cooperative Study - Activities of Daily Living Scale (ADCS-iADLS). In a structured interview format, informants are queried as to whether participants attempted each item in the inventory during the prior 4 weeks and their level of performance. Scores range from 0-56.

  8. Caregiver burden survey [ Time Frame: Baseline to visit 16 (14 weeks) ]
    Assessed per Zarit's burden 22-item questionnaire. Burden measured on a 5-point scale (0 = never burdened, 4 = nearly always burdened). Max score = 88

  9. Actigraphy sleep assessment - Total sleep time [ Time Frame: Screen to visit 16 (16 weeks) ]
    To assess standard sleep parameters using wearable devices (actigraph wristwatch): Total sleep time reported as time in minutes.

  10. Actigraphy sleep assessment - Wake after sleep onset [ Time Frame: Screen to visit 16 (16 weeks) ]
    To assess standard sleep parameters using wearable devices (actigraph wristwatch): Wake after sleep onset (WASO) reported as time in minutes.

  11. Actigraphy sleep assessment - Sleep efficiency [ Time Frame: Screen to visit 16 (16 weeks) ]
    To assess standard sleep parameters using wearable devices (actigraph wristwatch): Sleep efficiency reported as percentage.

  12. Physical activity [ Time Frame: Screen to visit 16 (16 weeks) ]
    To assess daily activity using wearable devices: FitBit.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   55 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Men or postmenopausal women, aged 55 years or older
  • Diagnosis of MCI due to AD or mild AD
  • In good general health as evidenced by medical history and with no medical contraindications to participation
  • MMSE > 20 at screen
  • Caregiver willing and capable to accompany the patient to clinic visits

Exclusion Criteria:

  • Daily use of benzodiazepines, sedative/hypnotics, anticonvulsants, antipsychotics, and other drugs that might interact with the GABA-A receptor complex.
  • Seizure disorder, history of stroke, focal brain lesion, traumatic brain injury, substance abuse, malignancy.
  • Clinically significant laboratory or ECG abnormality obtained at screening visit.
  • MRI indicative of significant abnormality, including but not limited to evidence of a single prior hemorrhage or infarct >1 cm3, multiple lacunar infarcts (>1) or evidence of a single prior infarct >1cm3, evidence of a cerebral contusion, encephalomalacia, aneurysms, vascular malformations, subdural hematoma, or space occupying lesions (e.g. abscess or tumor).
  • Has any contraindications for MRI studies, including claustrophobia, the presence of metal (ferromagnetic) implants, or a cardiac pacemaker that is not compatible with MRI.
  • Is currently enrolled in a clinical trial involving an off-label use of an investigational drug or device, or concurrently enrolled in any other type of medical research or observational study judged not to be scientifically or medically compatible with this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03748303


Contacts
Layout table for location contacts
Contact: Gerson Hernandez, MD, MPH 520+626-5781 gersonhe@email.arizona.edu
Contact: Claudia M Lopez, BS 520-626-6276 claudiml@email.arizona.edu

Locations
Layout table for location information
United States, California
University of Southern California - Alzheimer Disease Research Center - Healthcare Consultation Center II Recruiting
Los Angeles, California, United States, 90033
Sponsors and Collaborators
University of Arizona
University of Southern California
Alzheimer's Association
Investigators
Layout table for investigator information
Principal Investigator: Roberta D Brinton, PhD University of Arizona
Principal Investigator: Lon S Schneider, MD, MS University of Southern California

Layout table for additonal information
Responsible Party: Roberta Brinton, Professor, University of Arizona
ClinicalTrials.gov Identifier: NCT03748303    
Other Study ID Numbers: AlloPhase1-IM
First Posted: November 20, 2018    Key Record Dates
Last Update Posted: January 29, 2020
Last Verified: January 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Roberta Brinton, University of Arizona:
Alzheimer's disease
Mild cognitive impairment
Dementia
Regenerative therapeutic
Drug development
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Pregnanolone
Anesthetics
Central Nervous System Depressants
Physiological Effects of Drugs